Eva Ehlich and Anja Fux of Maiwald discuss a board of appeal decision on G 2/21’s interpretation, including a critical review of the interpretation in T 116/18 while denying a request for further review
Eva Ehlich and Anja Fux of Maiwald discuss an EPO board ruling relating to the standard of disclosure concerning the novelty and sufficiency of a therapeutic effect in the context of existing case law
Eva Ehlich and Anja Fux of Maiwald summarise an EPO board ruling relating to substances and compositions in the context of medical use claims and how it could affect applicants’ portfolio strategies
While some observers are of the view that an Enlarged Board of Appeal ruling failed to provide sufficient clarity, Eva Ehlich and Anja Fux of Maiwald say the picture concerning post-published evidence is becoming clearer
